Dopamine inhibits mitochondrial motility in hippocampal neurons

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Chen, Sigeng ^a   Owens, Geoffrey C ^a   Edelman, David B ^a  

^a NEUROSCIENCES INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GLYCOGEN SYNTHASE KINASE 3BETA; HALOPERIDOL; PROTEIN KINASE B; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 1A RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ANIMAL CELL; ARTICLE; BRAIN MITOCHONDRION; CELL TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE MICROSCOPY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MITOCHONDRIAL ENERGY TRANSFER; NERVE CELL; NERVE CELL CULTURE; NERVE FIBER TRANSPORT; NEUROMODULATION; NONHUMAN; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; METABOLISM; METHODOLOGY; MITOCHONDRION; NERVE FIBER; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; AXONS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; DOPAMINE; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; MICROSCOPY, FLUORESCENCE; MITOCHONDRIA; MODELS, BIOLOGICAL; NEURONS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D1;

EID: 50949084911     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002804     Document Type: Article

References (48)

1. Hollenbeck PJ, Saxton WM (2005) The axonal transport of mitochondria. J Cell Sci 118: 5411-5419.
2. Reynolds IJ, Malaiyandi LM, Coash M, Rintoul GL (2004) Mitochondrial trafficking in neurons: a key variable in neurodegeneration? J Bioenerg Biomembr 36: 283-286.
3. Trimmer PA, Borland MK (2005) Differentiated Alzheimer's disease transmitochondrial cybrid cell lines exhibit reduced organelle movement. Antioxid Redox Signal 7: 1101-1109.
4. Beal MF (2007) Mitochondria and neurodegeneration. Novartis Found Symp 287: 183-192; discussion 192-186.
5. Chada SR, Hollenbeck PJ (2004) Nerve growth factor signaling regulates motility and docking of axonal mitochondria. Curr Biol 14: 1272-1276.
6. De Vos KJ, Sable J, Miller KE, Sheetz MP (2003) Expression of phosphatidylinositol (4,5) bisphosphate-specific pleckstrin homology domains alters direction but not the level of axonal transport of mitochondria. Mol Biol Cell 14: 3636-3649.
7. Malaiyandi LM, Honick AS, Rintoul GL, Wang QJ, Reynolds IJ (2005) Zn2+ inhibits mitochondrial movement in neurons by phosphatidylinositol 3-kinase activation. J Neurosci 25: 9507-9514.
8. Rintoul GI, Filiano AJ, Brocard JB, Kress GJ, Reynolds IJ (2003) Glutamate decreases mitochondrial size and movement in primary forebrain neurons. J Neurosci 23: 7881-7888.
9. Chen S, Owens GC, Crossin KI, Edelman DB (2007) Scrotonin stimulates mitochondrial transport in hippocampal neurons. Mol Cell Neurosci 36: 472-483.
10. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, et al. (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122: 261-273.
11. Beaulieu JM, Gainetdinov RR, Caron MG (2007) The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 28: 166-172.
12. Beaulieu JM, Tirotta E, Sotnikova TD, Masri B, Salahpour A, et al. (2007) Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 27: 881-885.
13. Jackson DM, Westlind-Danielsson A (1994) Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol Ther 64: 291-370.
14. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78: 189-225.
15. Wise RA, Rompre PP (1989) Brain dopamine and reward. Annu Rev Psychol 40: 191-225.
16. Thomas B, Beal MF (2007) Parkinson's disease. Hum Mol Genet 16 Spec No. 2: R183-194.
17. Ben-Shachar D (2002) Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J Neurochem 83: 1241-1251.
18. Beau1ieu JM (2007) Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. Int J Neuropsychopharmacol 10: 3-6.
19. Aizman O, Brismar H, Uhlen P, Zettergren E, Levey AJ, et al. (2000) Anatomical and physiological evidence for D1 and D2 dopaimne receptor colocalization in neostriatal neurons. Nat Ncurosci 3: 226-230.
20. Dineley KE, Richards LL, Votyakova TV, Reynolds IJ (2005) Zinc causes loss of membrane potential and elevates reactive oxygen species in rat brain mitochondria. Mitochondrion 5: 55-65.
21. Ward MW, Rego AC, Frenguelli BG, Nicholls DG (2000) Mitochondrial membrane potential and glutamate excitotoxicity in cultured cerebellar granule cells. J Neurosci 20: 7208-7219.
22. Inazu M, Takeda H, Ikoshi H, Uchida Y, Kubota N, et al. (1999) Regulation of dopamine uptake by basic fibroblast growth factor and epidermal growth factor in cultured rat astrocytes. Neurosci Res 34: 235-244.
23. Inazu M, Kubota N, Takeda H, Zhang J, Kiuchi Y, et al. (1999) Pharmacological characterization of dopamine transport in cultured rat astrocytes. Life Sci 64: 2239-2245.
24. Neve KA, Seamans JK, Trantham-Davidson H (2004) Dopamine receptor signaling. J Recept Signal Transduct Res 24: 165-205.
25. Greengard P (2001) The neurobiology of slow synaptic transmission. Science 294: 1024-1030.
26. Brami-Cherrier K, Valjent E, Garcia M, Pages C, Hipskind RA, et al. (2002) Dopamine induces a P13-kinase-independent activation of Akt in striatal neurons: a new route to cAMP response element-binding protein phosphorylation. J Neurosci 22: 8911-8921.
27. Bozzi Y, Borrelli E (2006) Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it? Trends Neurosci 29: 167-174.
28. Brenner-Lavie H, Klein E, Zuk R, Gazawi H, Ljubuncic P, et al. (2007) Dopaimne modulates mitochondrial function in viable SH-SY5Y cells possibly via its interaction with complex 1: Relevance to dopamine pathology in schizophrenia. Biochim Biophys Acta.
29. Lee D, Huang W, Wang L, Copolov D, Lim AT (2000) Glucocorticoid modulation of dopamine mediated effects on hypothalamic atrial natriuretic factor neurons. Mol Psychiatry 5: 332-336.
30. Gerfen CR (2000) Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 23: S64-70.
31. Lemberger T, Parlato R, Dassesse D, Westphal M, Casanova E, et al. (2007) Expression of Cre recombinase in dopaminoceptive neurons. BMC Neurosci 8: 4.
32. Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, et al. (2003) A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425: 917-925.
33. George SR, O'Dowd BF (2007) A novel dopamine receptor signaling unit in brain: heterooligomers of D1 and D2 dopamine receptors. ScientificWorldJournal 7: 58-63.
34. Lee FJ, Xue S, Pei L, Vukusic B, Chery N, et al. (2002) Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111: 219-230.
35. Callier S, Snapyan M, Le Crom S, Prou D, Vincent JD, et al. (2003) Evolution and cell biology of dopamine receptors in vertebrates. Biol Cell 95: 489-502.
36. Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, et al. (2004) Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/ glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 101: 5099-5104.
37. Ahn JH, McAvoy T, Rakhilin SV, Nishi A, Greengard P, et al. (2007) Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56delta subunit. Proc Natl Acad Sci U S A 104: 2979-2984.
38. Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95-102.
39. Lao G, Scheuss V, Gerwin CM, Su Q, Mochida S, et al. (2000) Syntaphilin: a syntaxin-1 clamp that controls SNARE assembly. Neuron 25: 191-201.
40. Mookherjee P, Quintanilla R, Roh MS, Zmijewska AA, Jope RS, et al. (2007) Mitochondrial-targeted active Akt protects SH-SY5Y neuroblastoma cells from staurosporine-induccd apoptotic cell death. J Cell Biochem 102: 196-210.
41. Millan MJ (2004) The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur J Pharmacol 500: 371-384.
42. Tremblay P, Blier P (2006) Catecholaminergic strategies for the treatment of major depression. Curr Drug Targets 7: 149-158.
43. Zhang X, Andren PE, Greengard P, Svenningsson P (2008) Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc Natl Acad Sci U S A.
44. Weikop P, Kehr J, Scheel-Kruger J (2007) Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors. J Psychopharmacol 21: 795-804.
45. Frederick RL, Shaw JM (2007) Moving mitochondria: establishing distribution of an essential organelle. Traffic 8: 1668-1675.
46. Kang JS, Tian JH, Pan PY, Zald P, Li C, et al. (2008) Docking of axonal mitochondria by syntaphilin controls their mobility and affects short-term facilitation. Cell 132: 137-148.
47. Mistry SK, Keefer EW, Cunningham BA, Edelman GM, Crossin KL (2002) Cultured rat hippocampal neural progenitors generate spontaneously active neural networks. Proc Natl Acad Sci U S A 99: 1621-1626.
48. Curran MA, Kaiser SM, Achacoso PI, Nolan GP (2000) Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol Ther 1: 31-38.